NAYSAYERS
After years of being written off by skeptics, Bionano Genomics is about to turn the tables on the naysayers. What once was dismissed as “too niche” or “too unproven” has become the very foundation of tomorrow’s gold standard in genetic testing. Now, armed with a healthy balance sheet and a game-changing partnership with Illumina, Bionano will spotlight hidden DNA changes that nobody else can see, and make doubters eat their words.
As instruments roll into clinics and consumables are in demand, each new placement will stand as proof that thoughtful persistence beats short-sighted criticism. The naysayers will watch, with regret, as Bionano’s share price climbs alongside its reputation, and the company they once underestimated will emerge as the champion they disparaged.
ILMN $101.80 BNGO $4.02 going UP!
Market Data 
Markets 
AI
